MK-1775 (AZD1775), WEE1 Inhibitor


Catalog No. size PriceQuantity
M60299-2S 2 mg solid $129
M60299-10S 10mg solid $516

Description

MK-1775 (AZD1775) is a highly potent, selective and orally bioavailable Wee1 kinase inhibitor with IC50 of 5.2 nM. It abrogated DNA damaged checkpoints induced by gemcitabine, carboplatin, and cisplatin etc. and enhanced the anti-tumor efficacy of these agents selectively in p53-deficient tumor cells. At tolerated doses, MK-1775 treatment leads to xenograft tumor growth inhibition or regression. It inhibits Wee1 in H3K36me3-deficient cells results in RRM2 reduction, critical dNTP depletion, S-phase arrest, and apoptosis. MK-1775 can regresse H3K36me3-deficient tumor xenografts too. Right now MK-1775 is in phase I/II clinical trials for various cancers.

Product information

CAS Number: 955365-80-7

Molecular Weight: 500.60

Formula: C27H32N8O2

Synonym:

AZD1775

adavosertib

Chemical Name: 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one

Smiles: CN1CCN(CC1)C1C=CC(=CC=1)NC1=NC2=C(C=N1)C(=O)N(CC=C)N2C1=CC=CC(=N1)C(C)(C)O

InChiKey: BKWJAKQVGHWELA-UHFFFAOYSA-N

InChi: InChI=1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31)

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO up to 100 mM

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

MK-1775 was used at 1 µM in vitro and cellular assays.

In Vivo:

MK-1775 was orally dosed to mice at 20 mg/Kg once per day.

References:

  1. Hirai H, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. (2009) Mol Cancer Ther. 8(11):2992-3000.
  2. Rajeshkumar NV, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. (2011) Clin Cancer Res. 17(9):2799-806.
  3. Guertin AD, et al. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. (2013) Mol Cancer Ther. 12(8):1442-52.
  4. Pfister SX, et al. Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation. (2015) Cancer Cell. 28(5):557-68.

Products are for research use only. Not for human use.


Documents

Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed